The present study indicated that the expression of CREBBP was notably down-regulated in patients as compared with the controls, and was especially down-regulated in the GA/AA genotype subgroup, indicating that CREBBP may be used as a therapeutic target for DLBCL. This evidence concerns the gene CREBBP and diffuse large B-cell lymphoma.